We are excited to announce that Eagle IP has been named as the winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026.

The LSPN Awards recognize outstanding achievement, innovation, and leadership within the life sciences intellectual property community. The Cross-Border Collaboration Partner of the Year Award honors the non-US law firm that has demonstrated exceptional partnership with US law firms and life sciences companies through superior cross-jurisdictional expertise, strategic counsel, and seamless collaboration.

This award underscores the strength of our team’s commitment to delivering sophisticated, high-quality intellectual property services that effectively bridge Greater China and global markets. We remain dedicated to serving as a trusted partner to our US and international colleagues in advancing life sciences innovation through strategic patent protection and portfolio management.

Our President and Managing Director Ms. Jennifer Che traveled to Boston last week to accept the award on behalf of our entire team, as well as to speak at the LSPN two-day conference which preceded the awards ceremony.

We are truly honored to be named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026! This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration.


Explore the full list of winners from this year’s LSPN Awards USA: https://awards.newton.media/lspnawards2026/en/page/2026-winners

我們過去活動

Recommended Insights

New Policies to Promote Importation of Innovative Drugs

2018年11月8日
At the April 12, 2018 executive meeting of the State Council in China, Premier Mr. Li Keqiang indicated the government’s desire to increase China’s access to innovative drugs. To achieve this, the government would encourage importation of innovative drugs into China by streamlining the regulatory pathway, enhancing IP protection, and lowering the cost of medicine. […]

Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics

2026年7月14日
How the Supreme People's Court Established a New Benchmark for Unexpected Technical Effects in a Landmark Diabetic Nephropathy Case Proving inventive step for pharmaceutical compounds, especially a second medical use, remains one of the most challenging aspects of patent prosecution in China. When the prior art discloses a compound's general therapeutic properties, how can an […]

China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

2021年10月19日
The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]
China Patent 2020 to 2021

China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021

2020年4月23日
China continues to progress towards its major goal of significantly strengthening IP protection within its borders. Last year it announced several proposed amendments to its patent laws. In January 2020 China and the US signed the Economic and Trade Agreement between the Government of China and US (published 16 January 2020 –“Trade Agreement”), which detailed […]
Top crossarrow-right